Nuwellis, Inc. Q3 2026 Earnings Call Summary

Nuwellis reported Q3 2026 gross margin expansion to 70% and a 24% year-over-year improvement in operating loss. Pediatric sales grew 20% in the quarter, and the company submitted a 510(k) application to expand the Aquadex SmartFlow system indication. Management expects product launches in early 2027 and has $8.3 million in cash for a runway through Q2 2027. The company raised $8.1 million in the quarter.

Original reporting
Published Nov 12, 2026, 6:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 6:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nuwellis, Inc. Q3 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

Med
01

Why it matters

The earnings call provides fresh guidance on product launches and cash runway, offering traders new data points for valuation.

02

Market read

Micro‑cap earnings with modest financial improvements; may influence niche biotech investors.

03

What to watch

Potential regulatory delays for the 510(k) submission could stall growth initiatives.

Relevance 6/10Novelty 7/10Timing: post-earnings today

Background

Nuwellis, Inc. reported Q3 2026 results, highlighting margin expansion, operating loss reduction, and product pipeline updates.

Market effects

Limited impact on medtech sector; modest margin expansion may attract niche investors.

Primarily U.S. micro‑cap market; no broader regional effect.

Low global relevance given company size and niche focus.

Counterpoint

Despite margin improvement, cash runway is short; risk of dilution from upcoming financing.

Key entities

  • Nuwellis, Inc.

    Medical device maker focusing on pediatric renal therapies.

Related articles

$NUWEMed

Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in…

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss Console unit sales increased 88% year-to-date versus pri

$NUWEHighAI 8/10

Nuwellis submits FDA application for pediatric Aquadex expansion

Nuwellis (NASDAQ: NUWE) submitted a 510(k) application to the FDA to expand the use of its Aquadex SmartFlow System to pediatric patients weighing 5 kg and above, currently cleared for 20 kg and above. The submission includes clinical data from the ULTRA-Peds Registry and aims to provide treatment options for fluid overload in smaller children. The company's CEO and a medical director commented on the strategic importance and clinical benefits of the expansion.

$NUWEMed

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 13, 2026 Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin Recent capital raise and warrant exercises extend cash runway through second quarter

$NUWEMed

Nuwellis Slumps on Share Sale

Nuwellis (NASDAQ: NUWE) entered a definitive securities purchase agreement for a registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds of about $3.1 million from warrant exercises tied to its June 2026 offering. In a concurrent private placement, investors receive warrants for up to 1,310,890 shares at $2.59, exercisable immediately, expiring in five years. Closing expected around Aug. 3, 2026.

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.